Phase I/II Open Label Evaluation of Safety and Feasibility of 6 Months IV PRTX-100 Administrations in Previous Rheumatoid Arthritis Study Participants and Development of Immunological Samples for Assay Development From Normal Volunteers

Trial Profile

Phase I/II Open Label Evaluation of Safety and Feasibility of 6 Months IV PRTX-100 Administrations in Previous Rheumatoid Arthritis Study Participants and Development of Immunological Samples for Assay Development From Normal Volunteers

Completed
Phase of Trial: Phase I/II

Latest Information Update: 21 Apr 2017

At a glance

  • Drugs Staphylococcal-protein-A (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions
  • Acronyms SPARTA-II
  • Sponsors Protalex
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 05 May 2016 Status changed from recruiting to completed.
    • 25 Apr 2016 According to a Protalex media release, company expects to submit the final clinical report to the FDA in the next several months.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top